Anhui Fengyuan Pharmaceutical released the 2024 interim report. During the reporting period, the company achieved revenue of 2.308 billion yuan, a year-on-year increase of 0.98%; the net income attributable to shareholders of listed companies was 0.1 billion yuan, a year-on-year decrease of 2.72%.
丰原药业：上半年净利润同比减少2.72%
Anhui Fengyuan Pharmaceutical: The net income in the first half of the year decreased by 2.72% year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated